Lovenox Marketing Documents Subpoenaed By Chicago U.S. Attorney
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis is responding to a subpoena issued by the Chicago U.S. Attorney regarding "sales and marketing practices" for the low molecular weight heparin product Lovenox, the company disclosed Oct. 21
You may also be interested in...
Lovenox Discontinued Promotions Are “False,” But Corrective Ads Not Warranted – Court
Aventis’ claims that enoxaparin is “therapeutic from dose one” and “reaches therapeutic levels within ½ hour” are unsupported. However, the claim that Lovenox requires “no routine monitoring” is not literally false, the court says.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.